Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

Yaniv Lustig, Neta Zuckerman, Ital Nemet, Nofar Atari, Limor Kliker, Gili Regev-Yochay, Einav Sapir, Orna Mor, Sharon Alroy-Preis, Ella Mendelson, Michal Mandelboim*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in 36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres compared with the original virus: Gamma (P.1) 2.3, Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of the Alpha (B.1.1.7) variant was not significant. Despite being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is probably protective.

Original languageEnglish
Article number2100557
JournalEurosurveillance
Volume5
Issue number13
DOIs
StatePublished - 1 Jul 2021

Funding

FundersFunder number
Chaim Sheba Medical Center
Nehemia Rubin Excellence in Biomedical Research

    Fingerprint

    Dive into the research topics of 'Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel'. Together they form a unique fingerprint.

    Cite this